At the molecular level, in response to Ru-bdcurc treatment, cancer cells activated NRF2 and BiP pathways whose pharmacologic inhibition increased Ru-bdcurc-induced cell death, suggesting that they acted as death resistant mechanisms to the drug. The gene discussed is HSPA5; the disease is cancer.